EULAR definition of difficult-to-treat rheumatoid arthritis

被引:377
作者
Nagy, Gyorgy [1 ,2 ]
Roodenrijs, Nadia M. T. [3 ]
Welsing, Paco M. J. [3 ]
Kedves, Melinda [4 ]
Hamar, Attila [5 ]
van der Goes, Marlies C. [3 ,6 ]
Kent, Alison [7 ]
Bakkers, Margot [8 ]
Blaas, Etienne [3 ]
Senolt, Ladislav [9 ,10 ]
Szekanecz, Zoltan [5 ]
Choy, Ernest [11 ]
Dougados, Maxime [12 ]
Jacobs, Johannes W. G. [3 ]
Geenen, Rinie [13 ]
Bijlsma, Hans W. J. [3 ]
Zink, Angela [14 ,15 ]
Aletaha, Daniel [16 ]
Schoneveld, Leonard [17 ]
van Riel, Piet [18 ]
Gutermann, Loriane [19 ]
Prior, Yeliz [20 ]
Nikiphorou, Elena [21 ]
Ferraccioli, Gianfranco [22 ]
Schett, Georg [23 ,24 ]
Hyrich, Kimme L. [25 ,26 ]
Mueller-Ladner, Ulf [27 ]
Buch, Maya H. [25 ,26 ,28 ]
McInnes, Iain B. [29 ]
van der Heijde, Desiree [30 ]
van Laar, Jacob M. [3 ]
机构
[1] Semmelweis Univ, Dept Rheumatol, Dept Internal Med 3, Budapest, Hungary
[2] Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary
[3] Univ Utrecht, Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[4] Bacs Kiskun Cty Hosp, Dept Rheumatol, Kecskemet, Hungary
[5] Univ Debrecen, Fac Med, Dept Rheumatol, Debrecen, Hungary
[6] Meander Med Ctr, Dept Rheumatol, Amersfoort, Netherlands
[7] Salisbury Fdn Trust NHS Hosp, Salisbury, Wilts, England
[8] EULAR Standing Comm People Arthrit Rheumatism Eur, Zurich, Switzerland
[9] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic
[10] Inst Rheumatol, Prague, Czech Republic
[11] Cardiff Univ, CREATE Ctr, Sch Med, Sect Rheumatol,Div Infect & Immun, Cardiff, Wales
[12] Univ Paris, Hop Cochin, AP HP,Clin Epidemiol & Biostat, Dept Rheumatol,PRES Sorbonne Paris Cite,INSERM,U1, Paris, France
[13] Univ Utrecht, Dept Psychol, Utrecht, Netherlands
[14] Univ Med, Charite, Epidemiol Unit, German Rheumatism Res Ctr, Berlin, Germany
[15] Univ Med, Charite, Rheumatol, Berlin, Germany
[16] Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria
[17] Bravis Hosp, Dept Rheumatol, Roosendaal, Netherlands
[18] Radboud Univ Nijmegen, Med Ctr, Dept Rheumat Dis, Nijmegen, Netherlands
[19] Paris Descartes Univ, Hop Cochin, AP HP, Dept Pharm, Paris, France
[20] Univ Salford, Ctr Hlth Sci Res, Sch Hlth & Soc, Salford, Lancs, England
[21] Kings Coll London, Ctr Rheumat Dis, London, England
[22] Univ Cattolica Sacro Cuore, Sch Med, Rome, Italy
[23] Friedrich Alexander Univ Erlangen Nuremberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[24] Univ Klinikum Erlangen, Erlangen, Germany
[25] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[26] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Ctr Musculoskeletal Res, Manchester, Lancs, England
[27] Justus Liebig Univ Giessen, Kerckhoff Clin Bad Nauhe, Dept Rheumatol & Clin Immunol, Bad Nauheim, Germany
[28] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[29] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[30] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands
关键词
RECOMMENDATIONS;
D O I
10.1136/annrheumdis-2020-217344
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of >= 2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 16 条
[11]   Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey [J].
Roodenrijs, Nadia M. T. ;
de Hair, Maria J. H. ;
van der Goes, Marlies C. ;
Jacobs, Johannes W. G. ;
Welsing, Paco M. J. ;
van der Heijde, Desiree ;
Aletaha, Daniel ;
Dougados, Maxime ;
Hyrich, Kimme L. ;
McInnes, Iain B. ;
Mueller-Ladner, Ulf ;
Senolt, Ladislav ;
Szekanecz, Zoltan ;
van Laar, Jacob M. ;
Nagy, Gyorgy .
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (12) :1705-1709
[12]   2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis [J].
Singh, Jasvinder A. ;
Saag, Kenneth G. ;
Bridges, S. Louis, Jr. ;
Akl, Elie A. ;
Bannuru, Raveendhara R. ;
Sullivan, Matthew C. ;
Vaysbrot, Elizaveta ;
McNaughton, Christine ;
Osani, Mikala ;
Shmerling, Robert H. ;
Curtis, Jeffrey R. ;
Furst, Daniel E. ;
Parks, Deborah ;
Kavanaugh, Arthur ;
O'Dell, James ;
King, Charles ;
Leong, Amye ;
Matteson, Eric L. ;
Schousboe, John T. ;
Drevlow, Barbara ;
Ginsberg, Seth ;
Grober, James ;
St Clair, E. William ;
Tindall, Elizabeth ;
Miller, Amy S. ;
McAlindon, Timothy .
ARTHRITIS CARE & RESEARCH, 2016, 68 (01) :1-25
[13]   Proposal for a new nomenclature of disease-modifying antirheumatic drugs [J].
Smolen, Josef S. ;
van der Heijde, Desiree ;
Machold, Klaus P. ;
Aletaha, Daniel ;
Landewe, Robert .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :3-5
[14]   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs [J].
Smolen, Josef S. ;
Landewe, Robert ;
Breedveld, Ferdinand C. ;
Dougados, Maxime ;
Emery, Paul ;
Gaujoux-Viala, Cecile ;
Gorter, Simone ;
Knevel, Rachel ;
Nam, Jackie ;
Schoels, Monika ;
Aletaha, Daniel ;
Buch, Maya ;
Gossec, Laure ;
Huizinga, Tom ;
Bijlsma, Johannes W. J. W. ;
Burmester, Gerd ;
Combe, Bernard ;
Cutolo, Maurizio ;
Gabay, Cem ;
Gomez-Reino, Juan ;
Kouloumas, Marios ;
Kvien, Tore K. ;
Martin-Mola, Emilio ;
McInnes, Iain ;
Pavelka, Karel ;
van Riel, Piet ;
Scholte, Marieke ;
Scott, David L. ;
Sokka, Tuulikki ;
Valesini, Guido ;
van Vollenhoven, Ronald ;
Winthrop, Kevin L. ;
Wong, John ;
Zink, Angela ;
van der Heijde, Desiree .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :964-975
[15]   Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force [J].
Strehl, Cindy ;
Bijlsma, Johannes W. J. ;
de Wit, Maarten ;
Boers, Maarten ;
Caeyers, Nele ;
Cutolo, Maurizio ;
Dasgupta, Bhaskar ;
Dixon, William G. ;
Geenen, Rinie ;
Huizinga, Tom W. J. ;
Kent, Alison ;
de Thurah, Annette Ladefoged ;
Listing, Joachim ;
Mariette, Xavier ;
Ray, David W. ;
Scherer, Hans U. ;
Seror, Raphaele ;
Spies, Cornelia M. ;
Tarp, Simon ;
Wiek, Dieter ;
Winthrop, Kevin L. ;
Buttgereit, Frank .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) :952-957
[16]   Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence [J].
Thase, ME .
CNS SPECTRUMS, 2004, 9 (11) :808-821